Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
Saved in:
| Title: | Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2. |
|---|---|
| Authors: | Gong J; Cedars-Sinai Medical Center, Los Angeles, CA., Mita AC; Cedars-Sinai Medical Center, Los Angeles, CA., Wei Z; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Cheng HH; University of Washington, Seattle, WA., Mitchell EP; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA., Wright JJ; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Ivy SP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Gray RC; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Bethesda, MD., Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2024 Apr; Vol. 8, pp. e2300407. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Adaptive Clinical Trial |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
